Table 3 Comparison between COVID-19 patients with and without evidence of fibrosis. Non-fibrotic group (n =109); fibrotic group (n =101)
From: Predicting lung fibrosis in post-COVID-19 patients after discharge with follow-up chest CT findings
The studied group, N = 210 | Test | p value | ||
|---|---|---|---|---|
Non fibrotic, N = 109 | Fibrotic, N = 101 | |||
Age (years) | ||||
Mean ±SD | 49.26±13.36 | 58.81±14.82 | t test 4.91 | <0.001 |
Range | 18–76 | 24–94 | ||
Sex | ||||
Male | 76 (69.7%) | 73 (72.3%) | X2 0.17 | 0.65 |
Female | 33 (30.3%) | 28 (27.7%) | ||
Severity score | ||||
Mean ±SD | 7.55±3.32 | 15.20±3.34 | U 11.09 | <0.001 |
Range | 1–14 | 9–20 | ||
Consolidation/crazy-paving score | ||||
Mean ±SD | 5.42±3.55 | 12.63±4.22 | U 10.06 | <0.001 |
Range | 0–15 | 5–20 | ||
Lymphopenia | 64 (58.7%) | 79 (78.2%) | X2 9.2 | 0.002 |
Elevated high-sensitivity troponin | 17 (15.6%) | 28 (27.7%) | X2 4.6 | 0.03 |
High ferritin levels | 62 (56.9%) | 81 (80.2%) | X2 13.1 | <0.001 |
Elevated CRP | 90 (82.6%) | 95 (94.1%) | X2 6.6 | 0.01 |
Elevated d-dimer | 87 (79.8%) | 96 (95.0%) | X2 10.9 | 0.001 |
Length of hospital stay | ||||
Mean ±SD | 8.56±7.03 | 23.26±20.89 | U 8.26 | <0.001 |
Range | 1–37 | 2–170 | ||
ICU admission | ||||
No | 102 (93.6%) | 56 (55.4%) | X2 40.9 | <0.001 |
Yes | 7 (6.4%) | 45 (44.6%) | ||
Steroid | ||||
No | 27 (24.8%) | 7 (6.9%) | X2 12.3 | <0.001 |
Yes | 82 (75.2%) | 94 (93.1%) | ||